TD Asset Management Inc Purchases 14,707 Shares of Prothena Co. plc (NASDAQ:PRTA)

TD Asset Management Inc lifted its position in Prothena Co. plc (NASDAQ:PRTA) by 19.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 89,413 shares of the biotechnology company’s stock after acquiring an additional 14,707 shares during the period. TD Asset Management Inc owned 0.17% of Prothena worth $6,105,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. FMR LLC raised its position in shares of Prothena by 71.3% in the 1st quarter. FMR LLC now owns 6,762,025 shares of the biotechnology company’s stock worth $327,755,000 after acquiring an additional 2,814,753 shares in the last quarter. BlackRock Inc. raised its position in shares of Prothena by 4.0% in the 1st quarter. BlackRock Inc. now owns 3,624,627 shares of the biotechnology company’s stock worth $175,686,000 after acquiring an additional 139,559 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Prothena by 7.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,205,903 shares of the biotechnology company’s stock worth $193,156,000 after acquiring an additional 223,962 shares in the last quarter. State Street Corp raised its position in shares of Prothena by 20.0% in the 1st quarter. State Street Corp now owns 2,367,583 shares of the biotechnology company’s stock worth $86,583,000 after acquiring an additional 394,633 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Prothena by 28.4% in the 1st quarter. Wellington Management Group LLP now owns 2,266,078 shares of the biotechnology company’s stock worth $109,837,000 after acquiring an additional 501,185 shares in the last quarter. Institutional investors own 97.08% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on PRTA. Cantor Fitzgerald restated an “overweight” rating and issued a $129.00 price target on shares of Prothena in a research note on Monday, October 23rd. JMP Securities cut their price target on Prothena from $83.00 to $81.00 and set a “market outperform” rating on the stock in a research note on Friday, November 3rd. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Prothena in a research note on Friday, August 4th. Finally, StockNews.com upgraded Prothena from a “sell” rating to a “hold” rating in a research note on Monday, November 6th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $91.00.

Prothena Trading Up 0.1 %

Shares of PRTA opened at $34.10 on Tuesday. The business’s fifty day simple moving average is $43.36 and its two-hundred day simple moving average is $57.96. Prothena Co. plc has a 12 month low of $28.51 and a 12 month high of $79.65. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -24.01 and a beta of 0.45.

Insider Buying and Selling at Prothena

In other Prothena news, insider Michael J. Malecek sold 5,000 shares of the stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $55.01, for a total transaction of $275,050.00. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, COO Brandon S. Smith sold 4,000 shares of the stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $46.75, for a total transaction of $187,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Michael J. Malecek sold 5,000 shares of the stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $55.01, for a total value of $275,050.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,000 shares of company stock worth $2,005,770. Insiders own 28.20% of the company’s stock.

About Prothena

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.